AI systems will probably be able to, if not direct labs themselves, cut down a lot of the search space to only the most promising candidates. That’s basically what Isomorphic Labs is doing for candidate drug research. It doesn’t seem crazy that the same could be true for material sciences.

▲

RandomLensman a day ago | parent [-]

Maybe. Are we seeing any indication of increased success rates in stage 3 trials already for "AI drug candidates"?

Could also be that some things are not possible in some ways. I wonder if there is some general theory on "shortcuts".

	▲	jacquesm a day ago \| parent [-]
		Stage 1, yes, stage 2, it's a wash (for now at least), which does not promise much for stage 3, but it is still a bit early for that.